PERKIN-ELMER BEEFING UP PROTEIN ANALYSIS OFFERINGS THROUGH $360 MIL. PERSEPTIVE BIOSYSTEMS ACQUISITION; DEAL TO CLOSE BY END OF YEAR
This article was originally published in The Gray Sheet
Executive Summary
Perkin-Elmer's $360 mil. acquisition of PerSeptive Biosystems would combine PerSeptive's strength in advanced protein analysis technology with PE's broad line of DNA sequencing technologies. The combination would create a fully integrated technology platform in the field of biomedical research and drug discovery, PE says.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.